Gilead Sciences (GILD) received an 88% rating from Validea's P/B Growth Investor model, based on Partha Mohanram's strategy, which seeks low book-to-market stocks poised for sustained future growth. This score, indicating "some interest" for the large-cap biotechnology stock, reflects strong underlying fundamentals and valuation, with GILD passing most key financial metrics like return on assets and cash flow, though it notably failed the Research and Development to Assets criterion.
Gilead Sciences (GILD) has been flagged as a compelling large-cap growth stock by Validea's P/B Growth Investor model, which is based on Partha Mohanram's academic research for identifying sustainable growth companies. The stock achieved a score of 88%, a rating that signifies model interest, by meeting eight of the nine fundamental criteria. Strengths are evident in its financial health and operational stability, as demonstrated by passing tests for Return on Assets, Cash Flow from Operations to Assets, and low variance in both ROA and sales. However, a notable point of weakness was identified, as GILD failed the criterion for Research and Development to Assets. For a company in the Biotechnology & Drugs industry, where the R&D pipeline is a critical value driver, this specific failure warrants further investigation despite the otherwise strong quantitative profile.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
